Thu, May 8, 11:08 AM (4 days ago)
### Summary of Amylyx Pharmaceuticals, Inc. (AMLX) Q1 2025 Financial Performance **Financial Health:** - **Cash and Cash Equivalents:** $59.764K (March 31, 2025) vs. $77.391K (December 31, 2024) - **Marketable Securities:** $144.304K (March 31, 2025) vs. $99.110K (December 31, 2024) - **Total Assets:** $219.676K (March 31, 2025) vs. $193.634K (December 31, 2024) - **Total Liabilities:** $18.259K (March 31, 2025) vs. $28.869K (December 31, 2024) - **Total Stockholders' Equity:** $201.417K (March 31, 2025) vs. $164.765K (December 31, 2024) **Revenue and Profit Margins:** - **Product Revenue:** $0K (March 31, 2025) vs. $88.643K (March 31, 2024) - **Net Loss:** $35.907K (March 31, 2025) vs. $118.793K (March 31, 2024) - **Net Loss per Share:** $0.42 (March 31, 2025) vs. $1.75 (March 31, 2024) **Cash Flow:** - **Net Cash Used in Operating Activities:** $39.824K (March 31, 2025) vs. $489K (March 31, 2024) - **Net Cash Used in Investing Activities:** $43.659K (March 31, 2025) vs. $819K (March 31, 2024) - **Net Cash Provided by Financing Activities:** $65.662K (March 31, 2025) vs. $131K (March 31, 2024) **Quarterly Performance Discussion:** - **Revenue:** No product revenue due to the discontinuation of RELYVRIO®/ALBRIOZA™. - **Operating Expenses:** Significant reduction in research and development (R&D) and selling, general, and administrative (SG&A) expenses. - **Cash Flow:** Positive cash flow from financing activities offset by negative cash flows from operating and investing activities. **Trends and Uncertainties:** - **R&D and SG&A Expenses:** Decline in expenses due to restructuring and reduced commercial activities. - **Cash Position:** Sufficient cash to meet operating and capital expenditure requirements through 2026. - **Future Operations Impact:** Continued focus on clinical trials and potential commercialization of avexitide, AMX0035, and AMX0114. **Key Metrics:** - **R&D Expenses:** $22.119K (March 31, 2025) vs. $36.608K (March 31, 2024) - **SG&A Expenses:** $15.684K (March 31, 2025) vs. $57.759K (March 31, 2024) - **Interest Income:** $2.231K (March 31, 2025) vs. $4.326K (March 31, 2024) **Future Outlook:** - **Clinical Trials:** Ongoing and planned trials for avexitide, AMX0035, and AMX0114. - **Regulatory Approvals:** Potential approvals and commercial launches anticipated in the coming years. - **Financial Strategy:** Focus on cost management and strategic financing to support development and commercialization efforts.